Likewise, gastric cancer cells overexpress the inhibin β subunit, which activates NF-κB signaling by secreting activin B and converting them into pro-tumorigenic CAFs, suggesting that targeting the NF-κB pathway will have significant effects on the TME and can serve as a new approach to cancer therapy [92]. The gene discussed is NFKB1; the disease is cancer.